Core Insights - Baird Medical Investment Holdings Ltd. successfully participated in the 2025 American Thyroid Association Annual Meeting, showcasing its leadership in minimally invasive Microwave Ablation (MWA) technology and attracting significant global interest from medical professionals [1][5]. Company Overview - Baird Medical specializes in minimally invasive diagnostics and treatment, focusing on surgical robotic systems and innovative surgical instruments. The company aims to enhance patient outcomes through precision technology and advanced diagnostic solutions [6]. - The company is FDA 510(k)-certified and its solutions are utilized in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital and Columbia University Medical Center. Baird Medical is also the market leader in China for thyroid microwave ablation devices and consumables [6]. Conference Highlights - The company's exhibition booth at the ATA meeting served as a hub for leading endocrinologists, surgeons, and researchers, facilitating in-depth discussions and live demonstrations of MWA systems, emphasizing the technology's precision and clinical utility [2]. - A key session featured Dr. Emad Kandil, who presented data from over 200 MWA procedures, including a cohort of 19 patients where MWA was effective after failed Radiofrequency Ablation treatments, highlighting MWA's potential as a vital treatment alternative [3][4]. Clinical Evidence - Dr. Kandil concluded that Microwave Ablation is a novel, safe, and effective method for treating benign and malignant thyroid nodules in both adult and pediatric populations, offering advantages over other thermal ablation techniques [4].